Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
The combination of HD-MTX, rituximab, and orelabrutinib demonstrates high response rates and manageable toxicity in newly diagnosed PCNSL, supporting further evaluation in randomized trials.
Authors
- Yajing Zhao (ORCID: https://orcid.org/0000-0002-6288-8688)
- Yafei Yu (ORCID: https://orcid.org/0000-0001-8985-2987)
- Qiang He (ORCID: https://orcid.org/0000-0003-4845-6640)
- Ji Ma
- Guoqiang Liu (ORCID: https://orcid.org/0000-0002-8212-6875)
- Liang Wang (ORCID: https://orcid.org/0000-0001-9317-5253)
- Xinguang Liu (ORCID: https://orcid.org/0000-0002-1808-4498)
- Lei Xu (ORCID: https://orcid.org/0000-0003-3213-2924)
- Caifeng Sun
Institutions
- Shengli Oilfield Central Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Blood and Lymphatic Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/blctt.s556657
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province